How much cash does Whitehawk Therapeutics, Inc. Common Stock generate?

Whitehawk Therapeutics, Inc. Common Stock (WHWK) generated -$107.8M in operating cash flow over the trailing twelve months.

What is Whitehawk Therapeutics, Inc. Common Stock's free cash flow?

After $738.0K of capital expenditures, Whitehawk Therapeutics, Inc. Common Stock's free cash flow was -$107.8M over the trailing twelve months, down 102.5% year over year.

Where does Whitehawk Therapeutics, Inc. Common Stock's cash flow data come from?

Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Whitehawk Therapeutics, Inc. Common Stock WHWK Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	-$20.6M+67.7%	-$63.69M+3.2%	-$65.77M—	——
Depreciation and amortization	$78.9K-59.2%	$193.3K+14.4%	$169K—	——
Stock-based compensation	$9.87M-8.9%	$10.84M-9.3%	$11.95M—	——
Gain (loss) on sale of assets	$87.27M—	$0—	——	——
Change in accounts receivable	——	——	——	——
Change in inventories	——	——	——	——
Change in accounts payable	$3.92M—	——	——	——
Change in other assets	——	-$518K0.0%	-$518K—	——
Change in other liabilities	——	——	——	$0+100%
Change in operating lease liabilities	——	-$512K-2.0%	-$502K—	——
Net cash from operating activities	-$97.43M-63.6%	-$59.55M+0.2%	-$59.66M—	——
Capital expenditures	——	$1.65M-58.4%	$3.97M—	——
Purchases of investments	$148.69M+308%	$36.48M-43.4%	$64.44M—	——
Proceeds from maturities/sales of investments	$59.85M-5.5%	$63.34M-58.2%	$151.62M—	——
Proceeds from sale of businesses	——	$0—	——	——
Net cash from investing activities	——	——	$83.21M—	——
Proceeds from issuance of common stock	——	$0-100%	$78K—	——
Net cash from financing activities	——	$130K—	——	——
Net increase (decrease) in cash	——	-$34.22M—	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$1.53M+17.4%	$1.3M-58.5%	$3.14M—	——
Depreciation	——	——	——	——
Gain on sale of business and assets	$87.27M—	$0—	——	——
Operating lease liabilities	——	-$512K-2.0%	-$502K—	——
Increase (Decrease) in Prepaid Expense and Other Assets	$434K+115%	-$2.81M+21.9%	-$3.6M—	——
Operating Lease Expense Non Cash	——	$460K—	——	——
Divestiture of businesses, net of cash transferred	——	$0—	——	——
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments	$59.85M-5.5%	$63.34M-58.2%	$151.62M—	——
Payments Of Stock Issuance Costs	——	$0—	$0-100%	$322K-96.7%
Proceeds From Issuance Of Common Stock And Warrants	——	$0—	——	——
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction	——	——	$46K—	——
Increase Decrease In Operating Lease Liability	——	-$512K-2.0%	-$502K—	——
Stock Issuance Costs Incurred Included In Accounts Payable	——	——	——	——
Free cash flow	-$97.99M-60.1%	-$61.2M+3.8%	-$63.64M—	——
Free cash flow	-$97.99M-60.1%	-$61.2M+3.8%	-$63.64M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Whitehawk Therapeutics, Inc. Common Stock generate?: Whitehawk Therapeutics, Inc. Common Stock (WHWK) generated -$107.8M in operating cash flow over the trailing twelve months.
What is Whitehawk Therapeutics, Inc. Common Stock's free cash flow?: After $738.0K of capital expenditures, Whitehawk Therapeutics, Inc. Common Stock's free cash flow was -$107.8M over the trailing twelve months, down 102.5% year over year.
Where does Whitehawk Therapeutics, Inc. Common Stock's cash flow data come from?: Every line is extracted from Whitehawk Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.